BioSpace News Archive

Valent BioSciences (VBC) announced that Randy Martin Ph.D. has been named Global Technical Development Specialist for the company’s burgeoning soil health business. Martin, who had previously managed VBC’s R&D pipeline, brings more than 30 years of experience in the agricultural biologicals space.

ReNeuron Group plc announced that ReNeuron’s management team will participate in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 in New York City.

ALX Oncology announced that Jaume Pons, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 4:00 p.m. ET at the Grand Hyatt in New York, NY.

111, Inc. announced that the Company will participate in the Credit Suisse 2019 Asia Healthcare Corporate Days in Hong Kong, June 5-6, 2019.

The Seattle Sperm Bank announces the opening of its 3rd laboratory location, at 8950 Villa La Jolla Drive, Suite B214, La Jolla, CA 92037.

Coming sharp on the heels of a wave of anti-abortion bills passed in a number of states, Men’s Huddle International, a grassroots men’s organization, is calling on men across America to take responsibility for the roles they play in sponsoring, requiring, encouraging, and in some cases their irresponsibility and/or abuse, which often lead women to have abortions.

Kite, a Gilead Company, and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Hesperos, Inc. announced it has been selected to showcase its technology at the 2019 BIO International Convention.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), today filed its Notice of Meeting and Management Information Circular. Aurinia plans to host its upcoming Annual General Meeting of Shareholders (“AGM”) at 10:00 a.m. MT on Wednesday, June 26, 2019, at the Westin Calgary, 320 4th Ave SW in Calgary, Alberta.

WAT Medical, a company that develops safe, effective, and user-friendly wearable medical products, recently announced that HeadaTerm, its migraine treatment product, has received official clearance from TGA Australia.